Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Short term Debt (2021 - 2025)

Historic Short term Debt for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to $499.9 million.

  • Ascendis Pharma A's Short term Debt rose 209.08% to $499.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $499.9 million, marking a year-over-year increase of 209.08%. This contributed to the annual value of $485.3 million for FY2025, which is 89.5% down from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Short term Debt is $499.9 million, which was up 209.08% from $273.3 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Short term Debt registered a high of $499.9 million during Q4 2025, and its lowest value of $8.0 million during Q4 2021.
  • Over the past 5 years, Ascendis Pharma A's median Short term Debt value was $161.1 million (recorded in 2022), while the average stood at $192.6 million.
  • Per our database at Business Quant, Ascendis Pharma A's Short term Debt soared by 191382.77% in 2022 and then tumbled by 2406.51% in 2023.
  • Over the past 5 years, Ascendis Pharma A's Short term Debt (Quarter) stood at $8.0 million in 2021, then surged by 1913.83% to $161.1 million in 2022, then decreased by 4.33% to $154.2 million in 2023, then soared by 217.58% to $489.6 million in 2024, then grew by 2.09% to $499.9 million in 2025.
  • Its last three reported values are $499.9 million in Q4 2025, $273.3 million for Q3 2025, and $211.2 million during Q2 2025.